At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NBI NASDAQ Biotechnology
Market Closed 02-14 16:00:00 EST
4,521.85
-8.09
-0.18%
High4,577.22Low4,512.84Vol0.00
Open4,543.76D1 Closing4,529.94Amplitude1.42%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O--T/O Rate--Tradable Shares0.00
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
PR Newswire  ·  01-28
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Press Release: National Bank Investments Announces Revised Annual Reinvested Distribution Amounts for Its NBI Exchange-Traded Funds
Dow Jones  ·  01-03
Press Release: National Bank Investments Announces Revised Annual Reinvested Distribution Amounts for Its NBI Exchange-Traded Funds
National Bank Investments Announces the Annual Reinvested Distribution Amounts for Its NBI Exchange-Traded Funds
CNW Group  ·  2024-12-18
National Bank Investments Announces the Annual Reinvested Distribution Amounts for Its NBI Exchange-Traded Funds
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
GlobeNewswire  ·  2024-12-18
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
Business Wire  ·  2024-12-18
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
GlobeNewswire  ·  2024-12-17
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Exchange-Traded Funds, US Equities Higher After Midday Trading
MT Newswires Live  ·  2024-09-14
Exchange-Traded Funds, US Equities Higher After Midday Trading
Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target
MT Newswires Live  ·  2024-09-13
Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target
Exchange-Traded Funds, US Equities Trend Higher After Midday Trading
MT Newswires Live  ·  2024-09-13
Exchange-Traded Funds, US Equities Trend Higher After Midday Trading
Exchange-Traded Funds Lower, US Equities Mixed After Midday Trading
MT Newswires Live  ·  2024-09-12
Exchange-Traded Funds Lower, US Equities Mixed After Midday Trading
Exchange-Traded Funds, US Equities Lower After Midday Trading
MT Newswires Live  ·  2024-09-11
Exchange-Traded Funds, US Equities Lower After Midday Trading
Exchange-Traded Funds, US Equities Trend Higher After Midday Trading
MT Newswires Live  ·  2024-09-10
Exchange-Traded Funds, US Equities Trend Higher After Midday Trading
Buy Rating for Neurocrine Backed by Promising NBI-‘568 Drug Profile and Market Potential
TIPRANKS  ·  2024-09-09
Buy Rating for Neurocrine Backed by Promising NBI-‘568 Drug Profile and Market Potential
BRIEF-Nxera Pharma Says Receives $35 Mln From Neurocrine Biosciences Upon Positive Phase 2 Data For Partnered Schizophrenia Candidate NBI-1117568
Reuters  ·  2024-09-02
BRIEF-Nxera Pharma Says Receives $35 Mln From Neurocrine Biosciences Upon Positive Phase 2 Data For Partnered Schizophrenia Candidate NBI-1117568
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire  ·  2024-09-02
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Buy Rating Affirmed for Neurocrine’s NBI-1117568 Based on Safety, Tolerability, and Consistent Efficacy
TIPRANKS  ·  2024-08-29
Buy Rating Affirmed for Neurocrine’s NBI-1117568 Based on Safety, Tolerability, and Consistent Efficacy
Hold Rating on Neurocrine Amid Competitive Concerns for NBI-568
TIPRANKS  ·  2024-08-29
Hold Rating on Neurocrine Amid Competitive Concerns for NBI-568
BRIEF-Neurocrine Biosciences Reports Positive Phase 2 Data For NBI-1117568 In Adults With Schizophrenia
Reuters  ·  2024-08-28
BRIEF-Neurocrine Biosciences Reports Positive Phase 2 Data For NBI-1117568 In Adults With Schizophrenia
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire  ·  2024-08-28
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
PR Newswire  ·  2024-08-28
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

Introduction

Company Name.
NASDAQ Biotechnology
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--